Sobi wins contract to supply haemophilia therapies to Irish patients

Sobi has been awarded a contract that will see it make its drug available to patients in Ireland for the treatment of haemophilia B.

The Irish National Centre for Haemophilia and Coagulation Disorders at St James’ Hospital in Dublin recently signed a national contract that gives every person with haemophilia B requiring factor replacement therapy in Ireland access to the latest extended half-life therapies.

Following this, the Haemophilia Product Selection and Monitoring Advisory Board conducted an open tender to find a supplier for recombinant Factor IX therapies, with Sobi’s offer judged to provide the best value for Irish patients.

As such, it has been awarded the contract to supply its recombinant clotting factor therapy Alprolix for a minimum of two years. The drug, which was approved in the EU in May 2016, uses a naturally occurring pathway to extend the time the therapy remains in the body.

Paul Cox, Sobi’s business unit director for haemophilia in the UK and Ireland, said: “We’re delighted that the Irish authorities have taken the step to enable haemophilia B patients to access newly available therapies and have judged Alprolix to offer the best value for the Irish health system.”

This comes after the company was recently named as the leading haemophilia company in the UK by IPC Associates.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.